Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 15 of 27
 |<   <<   <  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  >   >>   >| 

Scientific Advancements
Thursday, May 13, 2021   (0 Comments - view/add)
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination »
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the T...
Wednesday, May 12, 2021   (0 Comments - view/add)
CDC Director Statement on Pfizer’s Use of COVID-19 Vaccine in Adolescents Age 12 and Older »
CDC Director Statement on Pfizer’s Use of COVID-19 Vaccine in Adolescents Age 12 and Older Media Statement For Immed...
Wednesday, May 12, 2021   (0 Comments - view/add)
Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for »
Johnson & Johnson Vision Announces FDA Approval of ACUVUE® Abiliti™ Overnight Therapeutic Lenses for Myopia Management...
Tuesday, May 11, 2021   (0 Comments - view/add)
AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two A »
AGTC Reports Process Development Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT -I...
Monday, May 10, 2021   (0 Comments - view/add)
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adoles »
Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents...
Friday, May 7, 2021   (0 Comments - view/add)
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approv »
Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of Their COVID 19 V...
Friday, May 7, 2021   (0 Comments - view/add)
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Subst »
KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classif ied as a Schedule IV Controlled Substance by the DEA...
Thursday, May 6, 2021   (0 Comments - view/add)
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical »
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial...
Monday, May 3, 2021   (0 Comments - view/add)
TherapeuticsMD Announces Poster Presentation of ANNOVERA® Data at the American College of Obstetrici »
TherapeuticsMD Announces Poster Presentation of ANNOVERA ® Data at the American College of Obstetricians and Gynecologist...
Thursday, April 29, 2021   (0 Comments - view/add)
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann- »
Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1...
Tuesday, April 27, 2021   (0 Comments - view/add)
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigati »
AIM ImmunoTech Announces Positive Safety Data in Second Cohort of Phase 1 Clinical Study Investigating Intranasal Admi...
Friday, April 23, 2021   (0 Comments - view/add)
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and »
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Followi...
Wednesday, April 21, 2021   (0 Comments - view/add)
BioCurity Pharmaceuticals Inc. Files a US Provisional Patent Application Drawn to Pharmaceutical For »
BioCurity Pharmaceuticals Inc. Files a US Provisional Patent Application Drawn to Pharmaceutical Formulations of Cerium...
Tuesday, April 20, 2021   (0 Comments - view/add)
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ i »
Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol ® Cyclo™ in Alzheimer’s Diseas...
Friday, April 16, 2021   (0 Comments - view/add)
Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye D »
Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clini...
Thursday, April 15, 2021   (0 Comments - view/add)
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for M »
Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Inve...
Tuesday, April 13, 2021   (0 Comments - view/add)
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzhei »
Longeveron Announces Positive Results of Phase I Clinical Study of Lomecel-B Cell Therapy for Alzheimer’s Disease...
Thursday, April 8, 2021   (0 Comments - view/add)
Morphogenesis Receives FDA Fast Track Designation »
Morphogenesis Receives FDA Fast Track Designation MORPHOGENESIS RECEIVES FDA FAST TRACK DESIGNATION FOR ITS CA...
Wednesday, April 7, 2021   (0 Comments - view/add)
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigatin »
AIM ImmunoTech Announces Positive Safety Data in First Cohort of Phase 1 Clinical Study Investigating Intranasal Admin...
Wednesday, April 7, 2021   (0 Comments - view/add)
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months »
Moderna Highlights Publication of Antibody Persistence Data of its COVID-19 Vaccine out to 6 Months in the New Englan...
Thursday, April 1, 2021   (0 Comments - view/add)
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Fo »
Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Do...
Tuesday, March 30, 2021   (0 Comments - view/add)
Biom Therapeutics Receives Orphan Drug Status for BIO017 from the U.S. FDA for the treatment of Ange »
Biom Therapeutics Receives Orphan Drug Status for BIO017 from the U.S. FDA for the treatment of Angelman Syndrome - The...
Monday, March 29, 2021   (0 Comments - view/add)
Update -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Cl »
Update -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Tri...
Thursday, March 25, 2021   (0 Comments - view/add)
BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™ »
BioStem Technologies, Inc. Receives TRIP (TRG Rapid Inquiry Program) Response for VENDAJE™ Pompano Beach, Fl., March 25,...
Thursday, March 25, 2021   (0 Comments - view/add)
The Development of Natural Killer Cells for Solid Tumor Treatment »
The Development of Natural Killer Cells for Solid Tumor Treatment Mar 25, 2021...
Thursday, March 25, 2021   (0 Comments - view/add)
AZD1222 US Phase III primary analysis confirms safety and efficacy »
AZD1222 US Phase III primary analysis confirms safety and efficacy 25 March 2021 00:45 GMT  ...
Thursday, March 25, 2021   (0 Comments - view/add)
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyc »
Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Diseas...
Thursday, March 25, 2021   (0 Comments - view/add)
Rapid Medical Receives FDA Clearance for the First Adjustable Stent Retriever for Use in Ischemic St »
Rapid Medical Receives FDA Clearance for the First Adjustable Stent Retriever for Use in Ischemic Stroke Treatment...
Wednesday, March 24, 2021   (0 Comments - view/add)
TIGER Trial Demonstrates High Safety and Efficacy for World’s First Adjustable Thrombectomy Device »
TIGER Trial Demonstrates High Safety and Efficacy for World’s First Adjustable Thrombectomy Device...
Tuesday, March 23, 2021   (0 Comments - view/add)
Tampa General Hospital-USF Health among first in nation to enroll patients in study of minimally inv »
Tampa General Hospital-USF Health among first in nation to enroll patients in study of minimally invasive treatment fo...
Monday, March 22, 2021   (0 Comments - view/add)
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in C »
AIM ImmunoTech Announces Addition of Single-Agent Ampligen Arm to Cancer Center’s Ongoing Study in Cancer Patients with CO...
Monday, March 22, 2021   (0 Comments - view/add)
Evren Technologies completes Phoenix™ Pilot Study with Excellent Results »
FOR IMMEDIATE RELEASE                 &nb...
Monday, March 22, 2021   (0 Comments - view/add)
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants »
Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants  Expanding existing COVID-19 vaccine resea...
Monday, March 22, 2021   (0 Comments - view/add)
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis »
AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis 22 March 2021 0...
Thursday, March 18, 2021   (0 Comments - view/add)
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 »
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100 Is...

Displaying page 15 of 27
 |<   <<   <  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  >   >>   >| 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)